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Individual cancer cells can exhibit striking differences in tumorigenic potential following experimental
transplantation, but themolecular pathways that regulate this activity remain poorly understood. In this issue
of Cancer Cell, Blackburn and colleagues report that Akt signaling regulates both leukemia-propagating
potential and proliferation rate via distinct pathways in T-ALL.Cancers arise as clonal outgrowths from
individual transformed cells, but the
resultant population of tumor cells often
harbors extensive phenotypic variability.
Of particular interest is the observation
that different cells of an individual
cancer can exhibit marked differences
in disease-propagating activity following
transplantation into unaffected reci-
pients, suggesting fundamental differ-
ences in their tumorigenic properties.
One model to explain these differences
is the cancer stem cell model, which
posits that a subpopulation of cancer
cells harbors a tumor’s disease-propa-
gating potential, and this cancer stem
cell population gives rise to a ‘‘bulk’’
cancer cell population that lacks tumor-
propagating potential. This model is
well supported by experimental evidence
in several tumor types, including acute
myeloid leukemia (Lapidot et al., 1994),
but equally convincing evidence argues
against this model in other tumors such
as melanoma (Quintana et al., 2008).
Independent of the cancer stem cell
model, genetic mutations, epigenetic
alterations, and/or environmental influ-
ences, can give rise to distinct tumor
subclones with extensive functionalvariation within the disease-propagating
population.
Limiting-dilution transplantation exper-
iments to assess tumor-propagating
potential have emerged as a promising
experimental tool to interrogate func-
tional variability among tumor cell popu-
lations. In this issue of Cancer Cell,
Blackburn and colleagues began their
investigation of phenotypic variegation
in T cell acute lymphoblastic leukemia
(T-ALL) leukemia-propagating cells
(LPC) using the limiting-dilution trans-
plantation assay in a zebrafish model of
Myc-induced T-ALL (Blackburn et al.,
2014). In this transplantation tour-de-
force, 16 fluorescently labeled primary
T-ALLs were subjected to serial limiting-
dilution transplantation into syngeneic
recipients (n = 6,024 transplantations) to
assess the evolution of LPC frequency
and time to T-ALL onset (latency) in
distinct subclones derived from a com-
mon ancestral progenitor.
The authors show that, although the
LPC frequency of individual clones is rela-
tively stable following serial transplanta-
tion, most primary T-ALLs (81%) harbor
clones with functional heterogeneity, as
evidenced by variations in latency andLPC frequency. Importantly, they demon-
strate that LPC frequency can be un-
coupled from leukemic growth rate and
disease latency, arguing that the path-
ways that control tumor latency versus
LPC potential can evolve independently.
The authors then investigated potential
molecular mechanisms involved and
found that evolution of increasing LPC
frequency was associated with Akt
pathway activation. Expression of con-
stitutively active Akt cooperated with
transgenic Myc or intracellular (constitu-
tively active) notch1a to accelerate leuke-
mia onset and increase LPC frequency,
implicating Akt signaling as a key regu-
lator of these phenotypes.
The authors then investigated the con-
tribution of two key pathways down-
stream of Akt to these phenotypes:
Gsk3b-dependent inhibition of Myc
degradation and Tsc-dependent activa-
tion of Rheb, which is best known as a
positive regulator of mammalian target
of rapamycin complex 1 (mTorc1) activity.
Surprisingly, expression of constitutively
active Rheb increased LPC frequency
without accelerating tumor onset. By
contrast, expression of a Myc T58A
mutant that is resistant to proteasomal5, March 17, 2014 ª2014 Elsevier Inc. 263
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Figure 1. Akt Regulates Leukemia-Propagation Potential and
Proliferation via Distinct Downstream pathways
Clonal evolution can lead to the emergence of subclones with increased
leukemia-propagating potential, often due to activation of the Akt pathway.
Akt directly phosphorylates and inactivates the Tsc complex, resulting in
relief of repression of Rheb, a GTPase best known as a positive regulator
of mTorc1 activity. Rheb activation results in a specific increase in T-ALL
cells with leukemia-propagating potential without increasing proliferation
or shortening time to T-ALL development, an effect that is likely mediated
by mTorc1. Akt also phosphorylates Gsk3b, resulting in inhibition of
Gsk3b-dependent phosphorylation of Myc at T58, leading to stabilization
of Myc protein levels. Overexpression of a Myc T58A mutant that mimics
the effect of the Akt-Gsk3b pathway on Myc stabilization accelerates T-ALL
proliferation, but had no measurable impact on leukemia-propagating
potential. As previewed in this article, Blackburn et al. (2014) show that these
Akt-positive LPCs can be targeted by the combination of Akt inhibitor and
dexamethasone.
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ation and accelerated T-ALL
onset, but had no effect on
LPC frequency. These ge-
netic studies suggest that
Akt stimulates leukemic pro-
liferation and accelerates the
onset of leukemia by stabiliz-
ing Myc, whereas increases
in LPC frequency reflect
Akt-mediated effects on
the Rheb-mTorc1 pathway
(Figure 1).
The finding that tumor-
propagating activity can be
regulated independent from
proliferation rate or latency
raises an intriguing ques-
tion: what are the cellular
mechanisms that specifically
enhance tumor-propagating
activity? One intriguing pos-
sibility is an alteration in the
kinetics of asymmetric cell
division within T-ALL cancer
stem cells, leading to an
increase in cancer stem
cell frequency within the
T-ALL population. This possi-
bility obviously requires that
T-ALL fit the cancer stem
cell model, and, although
not yet demonstrated irrefut-
ably, the available data are
consistent with this possibil-
ity. Indeed, identifiable sub-
sets of human and murine
T-ALL cells harbor increased
LPC activity, although dis-
crepancies in the immuno-
phenotypic subpopulation
harboring this activity inhuman T-ALL have been reported (see,
for example, Chiu et al., 2010). These
discrepancies may reflect biologic differ-
ences among distinct molecular T-ALL
subtypes or potentially result from differ-
ences in experimental methodology,
which can have a substantial impact on
the observed frequency of tumor-propa-
gating cells in specific subpopulations
(Quintana et al., 2008; Taussig et al.,
2008). In addition, LPC potential was
recently shown to be enriched within
a MYC-high subpopulation of murine
T-ALL, and transplantation of these
MYC-high LPCs resulted in generation of
leukemias that recapitulate the variability
of MYC expression observed in primary264 Cancer Cell 25, March 17, 2014 ª2014 Emouse T-ALLs (King et al., 2013). Further-
more, depletion or inhibition of MYC elim-
inates the LPC population and prevents
disease initiation, demonstrating a critical
role for MYC in LPC function (King et al.,
2013; Roderick et al., 2014). However, in
the zebrafish, overexpression of stabi-
lized Myc had no additional effect on
LPC frequency above that induced by
wild-type Myc overexpression. Potential
explanations for this might be that the
mouse studies involved Myc under the
control of its endogenous gene-regulatory
elements, leading to differentiation stage-
specific regulation of Myc expression.
Alternatively, the effects of MYC activity
on LPC function may require MYC levelslsevier Inc.above certain thresholds,
but far exceeding such a
threshold may have little addi-
tional effect on LPC potential.
Nonetheless, the available
data can also be explained
by several possibilities inde-
pendent of the cancer stem
cell model. For example,
although the cancer stem cell
model posits unidirectional
differentiation of stem cells
into ‘‘bulk’’ tumor cells, evi-
dence suggests that this
phenotypic change may be
bidirectional, as some bulk
tumor cells can give rise
to stem cell-like progenitors
(Chaffer et al., 2011). Thus,
Akt-Rheb pathway activa-
tion may promote the clonal
evolution of non-LPC into
LPC, with the Akt-Gsk3b-Myc
pathway independently con-
trolling proliferation of the
tumor cell population.
Alternatively, Akt-Rheb-
mTor pathway activation may
promote leukemic cell fitness
through the transplantation
procedure. Blackburn et al.
(2014) used transplantation of
fluorescently sorted cells in
syngeneic zebrafish, which
avoids a number of poten-
tially problematic experi-
mental steps, such as the
barrier to cross-species trans-
plantation resulting from the
failure of some growth factor
ligand-receptor interactions
across species or the use ofantibodies against cell surface antigens
that can trigger tumor cell destruction
(Taussig et al., 2008). However, none of
the available methods to assess tumor-
propagating activity avoid all potential
problems, and the methods used by the
authors require T-ALL cells to survive
outside of their native microenviron-
ment during cell sorting and hetero-
topic transplantation, and the use of
immunocompetent recipients allows
the possibility of an immune response
against tumor antigens. Nevertheless,
despite the seemingly artificial nature of
such experimental barriers, a tumor cell’s
resistance to proapoptotic stimuli and
to an antitumor immune response may
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sistance to conventional cytotoxic chem-
otherapy (Ni Chonghaile et al., 2011).
Moreover, transplantation of human
T-ALL into mice is associated with clonal
evolution that closelymimics the evolution
observed in human patients between
diagnosis and relapse (Clappier et al.,
2011), highlighting the relevance of
this approach to treatment resistance in
humans.
The findings of Blackburn et al. (2014)
have clear potential translational impli-
cations, because they suggest that AKT
activation in T-ALL cells with LPC poten-
tial may be poised to mediate treatment
resistance and relapse. The authors
show that these cells can be effec-
tively targeted by the combination of
dexamethasone and AKT inhibitors,
potentially due to reversal of AKT-
mediated dexamethasone resistance
(Piovan et al., 2013), thus providing an
additional rationale for clinical trialstesting such a strategy in high-risk
T-ALL.ACKNOWLEDGMENTS
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Tumors arise from single cells but become genetically heterogeneous through continuous acquisition of
somatic mutations as they progress. In this issue of Cancer Cell, Klco and colleagues used whole genome
sequence analysis to demonstrate the correlation of genetic clonal architecture with functional heterogeneity
in acute myeloid leukemia.A major tenet of cancer biology is that
tumors are clonal reflecting their origins
from single cells. This is best illustrated
by early seminal cytogenetic studies
demonstrating that all cells of a patient’s
leukemia, for example, may harbor a spe-
cific chromosomal aberration. However,
it has also been recognized for decades
that leukemias and solid tumors are het-
erogeneous in their genetic composition
such that, despite sharing a specific
chromosomal aberration, not all cells of
a given cancer demonstrate a completely
identical cytogenetic profile. This intratu-
moral genetic heterogeneity extends tothe level of individual genes and DNA
mutations as shown by next-generation
sequencing technologies and is fully
expected based on the fact that tumor
(and normal) cells acquire new mutations
with each cell division. At a practical
level, somatically acquired mutations
that accumulate at defined frequencies
can distinguish individual cells or tumor
subclones and serve as a clock to mark
and track their divergence from a com-
mon ancestor cell. The complexity of
clonal architecture has been shown
in hematological malignancies, includ-
ing acute lymphoblastic leukemia (ALL)(Anderson et al., 2011) and acute myeloid
leukemia (AML) (Ding et al., 2012) as well
as other cancer types such as breast
carcinoma (Shah et al., 2009), and is likely
a universal feature of all cancers. It is also
known that subpopulations of cells in
an individual tumor can be morphologi-
cally or functionally distinct, e.g., display
sensitivity or resistance to therapeutic
agents. However, the relationship be-
tween intratumoral genetic heterogeneity
and cancer cell function has not been
well defined. Nevertheless, clonal evolu-
tion has major implications for under-
standing the cellular hierarchies and5, March 17, 2014 ª2014 Elsevier Inc. 265
